Boundless Bio intiated with Not Rated at Goldman Sachs

Goldman Sachs analyst Chris Shibutani initiated coverage of Boundless Bio with a Not Rated and no price target. Boundless is a clinical-stage biotechnology company dedicated to developing oncology therapeutics for oncogene-amplified tumors by targeting extrachromosomal DNA, the analyst tells investors in a research note. The firm believes the company’s overall strategy targeting oncogene amplified tumors has the potential to deliver meaningful value to highly underserved patient populations that represent attractive commercial opportunities.